CT
CORT icon

Colonial Trust’s Corcept Therapeutics CORT Stock Holding History

Colonial Trust’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.64K Buy
53
+17
+47% +$1.03K ﹤0.01% 886
2026
Q1 		$1.38K Hold
36
– – ﹤0.01% 1046
2025
Q4 		$1.26K Hold
36
– – ﹤0.01% 1020
2025
Q3 		$3.01K Sell
36
-5
-12% -$362 ﹤0.01% 942
2025
Q2 		$2.98K Sell
41
-10
-20% -$725 ﹤0.01% 930
2025
Q1 		$2.8K Sell
51
-10
-16% -$609 ﹤0.01% 927
2024
Q4 		$3.13K Sell
61
-1,919
-97% -$101K ﹤0.01% 1156
2024
Q3 		$91.6K Buy
+1,980
New +$70.4K 0.01% 462

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Colonial Trust's CORT Position: Q2 2026 in Review

Colonial Trust increased its Corcept Therapeutics (CORT) stake by 47% in Q2 2026, buying an estimated $1.03K and bringing the position to 53 shares worth $4.64K. The position accounts for ﹤0.01% of the portfolio, ranked #886.

Colonial Trust first reported a position in CORT in Q3 2024 and has held it in 8 quarters since. The position peaked at $91.6K in Q3 2024. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Colonial Trust held 53 shares of Corcept Therapeutics worth $4.64K as of Q2 2026.
  • Colonial Trust bought 17 Corcept Therapeutics shares in Q2 2026, an estimated $1.03K.
  • Corcept Therapeutics made up ﹤0.01% of Colonial Trust's portfolio in Q2 2026, its #886 holding.
  • Colonial Trust first reported a position in Corcept Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Colonial Trust's Corcept Therapeutics position peaked at $91.6K in Q3 2024.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Colonial Trust's 13F filing for Q2 2026, filed 11 Aug 2026.